Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00879827 | Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infants | PHASE3 | COMPLETED | 60 | — | — | Sep 1, 2000 | May 1, 2001 | Sep 7, 2016 | - | — |
| Arm | Type | Description |
|---|---|---|
| Single Group | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Pediarix TM, Infanrix penta TM | BIOLOGICAL | The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age. |
| Hiberix TM | BIOLOGICAL | The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age. |
Inclusion Criteria: * A male or female infant between 6 and 8 weeks of age at the time of the first vaccination. * Free of obvious health problems as established by medical history and clinical examination before entering into the study. * Written informed consent obtained from the parents or guard...